CPI-613 receives FDA Fast Track Designation for treatment of AML

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has granted Fast Track designation to CPI-613 (devimistat) for the treatment of acute myeloid leukemia.

CPI-613 is sponsored by Rafael Pharmaceuticals Inc.

Rafael Pharmaceuticals received Fast Track designation for devimistat for the treatment of metastatic pancreatic cancer in November 2020. The company also received Orphan Drug Designation for the treatment of soft tissue sarcoma for devimistat, and the initiation of a phase II clinical trial of devimistat in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue.

Table of Contents

YOU MAY BE INTERESTED IN

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login